Loading…

SKBP326030.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major

Korean biopharma that developed and markets Xcopri (cenobamate), an epilepsy drug, directly in the US through its own subsidiary.

Momentum leader 87
Mkt cap
$5.03B
US dollars, full cap
Free float
50%
of shares outstanding
$/day
$15.2M
20-day average traded
Fwd P/E
21.5×
forward earnings
ROIC−WACC
+36.0 pp
WACC 5.6%
Hurdle
-98 pp
Req g minus delivered
Next earnings
84 days
10 Feb 2027
Close · KRW₩85,900
1D-3.5%
1W-0.9%
1M+15.3%
3M-1.6%
6M-16.1%
YTD-31.1%
1Y-28.1%
ATR %4.9%
52w lowhigh40.4% off high

What SKBP does

Korean biopharma that developed and markets Xcopri (cenobamate), an epilepsy drug, directly in the US through its own subsidiary.

Earns product sales of Xcopri directly in the US, and licence fees and royalties from partners that sell it elsewhere: in Europe Angelini Pharma markets it as Ontozry. Its own US sales team means it keeps the full revenue from its main market. Controlled by SK Inc., the Korean conglomerate's holding company.

Products and services

  • Xcopri/Ontozry (cenobamate)
  • CNS drug pipeline

Customers

  • US neurologists/epilepsy patients (via SK Life Sci
  • European/global licensing partners

Where it sits in the supply chain

  • Pharmaceuticals
  • CNS (epilepsy) drug development
  • Direct US commercialization

What could go right

  • Xcopri US prescription growth
  • European/international launches

What could go wrong

  • Single-drug revenue concentration
  • US biotech commercialization cost

Moat: narrow (IP / patents, regulatory licence). Patented epilepsy drug with FDA approval and its own US sales force, unusual for a Korean biopharma.

Headquarters: Seongnam, South Korea · Founded: 2011 · Employees: 272

Named competitors

SKBP at a glance

Size SKBP (326030.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $5.03B, the 81st largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩85,900 on 18 Nov 2026.

Performance Over six months the shares fell 16.1%, against +10.6% for the median peer and -37.2% for the South Korea market (cap-weighted) — 3rd lowest of 21 in its peer set.

Growth Revenue grew 37.4% over the last twelve months (peer median +11.3%); the operating margin is 37.6% (peer median 20.6%).

Valuation It trades at 21.5× forward earnings against a peer median of 28.7× (8th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +94%, so the hurdle is -98 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 36.0 points above its cost of capital (5.6% WACC).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 112326030.KS 89
Six months, rebased to 100: SKBP against the median of its 20 peers (local-currency closes).

SKBP financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩928B₩707B₩548B₩355B₩246B
Revenue growth—+29%+54%+44%—
Gross profit₩863B₩652B₩492B₩308B₩197B
EBITDA₩365B₩221B₩114B-₩22.8B-₩118B
Net income₩381B₩267B₩241B-₩32.9B-₩139B
Free cash flow₩273B₩174B₩91.5B-₩98.2B-₩165B
Capital expenditure₩32.5B₩29.5B₩13.4B₩3.25B₩5.96B
Total debt₩43.6B₩48.9B₩184B₩178B₩156B

Quarterly statements and history in the cockpit →

SKBP competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%0%+20%PTCTIPCALABLQDA600085600079ERASTVTXMANEGLAXO688578EMCUREIONS6030870874GLANDAJANTPHARMABBOTINDIA600566CAMX326030.KS6-month return →1-month return →
Up and to the right = strong over both horizons. SKBP is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%+600%+800%20×40×PTCTIPCALABLQDA600085600079TVTXGLAXO6885784506EMCURE6030870874GLANDCAMX326030.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. SKBP is the large dot.

Capital: growth delivered against growth the price implies

0%+200%+400%0%200%400%PTCTIPCALABLQDA600079688578326030.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. SKBP is the large dot.

SKBP competitors and peer comparison

Head to head with its named competitors (326030.KS vs JAZZ vs 4523.T vs SUPN)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
SKBP 326030.KS$5.03B-16%+37%38%21.5×-4.4%
Jazz Pharmaceuticals Public JAZZ$15.9B+4%+13%25%9.3×-2.8%
Eisai 4523.T$9.36B+11%+11%6%26.6×10.7%
Supernus Pharmaceuticals SUPN$6.02B-41%+16%45%8.0×6.2%
Xenon Pharmaceuticals XENE$3.71B-31%-100%n/an/an/a
Praxis Precision Medicines PRAX$8.53B-9%-100%n/an/an/a

How SKBP compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

SKBP against its 20 peers (data as of 18 Nov 2026)
Measure326030.KSPeer medianRank in peer set
1-month return+15.3%-1.2%4th highest of 21
6-month return-16.1%+10.6%3rd lowest of 21
Distance from 52-week high-40.4%-21.1%5th lowest of 21
Revenue growth (TTM)+37.4%+11.3%4th highest of 19
Operating margin37.6%20.6%4th highest of 19
Forward P/E21.5×28.7×8th cheapest of 18
Growth the price implies (Req g, 7 yrs)-4.4%7.3%3rd least demanding of 17
Growth delivered (Del g)+93.6%+12.5%3rd highest of 17
Hurdle (Req g minus delivered)-98.0 pp-2.6 pp3rd least demanding of 17
ROIC minus cost of capital+36.0 pp+4.6 pp5th highest of 17
EV / EBITDA17.2×22.8×4th cheapest of 11
Net debt / EBITDA-1.2×-0.7×5th least indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
SKBP 326030.KSSouth Korea$5.03B-16%+37%38%21.5×-4.4%+93.6%
PTC Therapeutics PTCTUnited States$5.03B-15%-35%22%31.2×6.6%+35.4%
IPCA Laboratories IPCALAB.NSIndia$5.03B+12%+12%18%31.1×16.5%+12.2%
Liquidia LQDAUnited States$5.08B-9%+798%47%13.8×5.0%+192.5%
Beijing TongRenTang 600085.SSChina$4.91B-12%-17%8%28.7×1.7%+6.2%
Humanwell Healthcare (Group) 600079.SSChina$4.87B+11%+2%15%13.8×-8.8%+3.0%
Erasca ERASUnited States$4.83B+24%n/an/an/an/an/a
Travere Therapeutics TVTXUnited States$4.82B+16%+49%-3%17.1×17.3%+19.9%
Veradermics MANEUnited States$5.27B+19%n/an/an/an/an/a
GlaxoSmithKline Pharmaceuticals GLAXO.NSIndia$4.79B+10%+12%33%37.3×26.4%+5.5%
Shanghai Allist Pharmaceuticals 688578.SSChina$5.32B-14%+39%47%12.4×0.1%+519.6%
Sumitomo Pharma 4506.TJapan$5.33B+11%+11%10%8.6×1.7%-2.6%
Emcure Pharmaceuticals EMCURE.NSIndia$4.74B+37%+21%16%33.6×15.9%+12.7%
Ionis Pharmaceuticals IONSUnited States$4.56B-64%-1%-59%n/an/an/a
Gan & Lee Pharmaceuticals 603087.SSChina$5.59B+11%+14%20%25.8×n/an/a
Guangzhou Baiyunshan Pharmaceutical 0874.HKHong Kong$4.48B-23%+6%3%7.0×1.3%+4.0%
Gland Pharma GLAND.NSIndia$5.71B+44%+22%21%39.3×20.2%+13.3%
Ajanta Pharma AJANTPHARM.NSIndia$4.38B+1%+25%25%31.7×23.8%+13.8%
Abbott India ABBOTINDIA.NSIndia$5.80B-8%+7%28%31.1×8.0%+10.0%
HUBEI JUMPCAN PHARMACEUTICAL 600566.SSChina$4.36B+12%-4%32%16.2×-9.9%+0.3%
Camurus CAMX.STSweden$4.36B+36%+3%38%45.1×7.9%+46.5%

Questions

Who are SKBP's main competitors?
Named competitors: UCB (private or unlisted), Jazz Pharmaceuticals (JAZZ), Eisai (4523.T), Supernus Pharmaceuticals (SUPN), Lundbeck (private or unlisted), Xenon Pharmaceuticals (XENE). The cockpit's measured peer set (industry) also includes PTC Therapeutics (PTCT), IPCA Laboratories (IPCALAB.NS), Liquidia (LQDA), Beijing TongRenTang (600085.SS), Humanwell Healthcare (Group) (600079.SS), Erasca (ERAS).
Is SKBP expensive compared with its peers?
On forward p/e it trades at 21.5× against a peer median of 28.7×, 8th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +94%, so the hurdle is -98 pp: the price already allows for a slowdown.
How has SKBP stock performed?
Over six months to 18 Nov 2026 the shares returned -16.1% against +10.6% for the median peer; over one year -28.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.